MODIFY THE DOSAGE OF ACYCLOVIR IN SEVERE RENAL FAILURE

InPharma ◽  
1982 ◽  
Vol 346 (1) ◽  
pp. 14-14
Keyword(s):  
Renal Failure ◽  
Severe Renal Failure

Platelet Function and the Bleeding Time in Progressive Renal Failure

1988 ◽  
Vol 60 (01) ◽  
pp. 083-087 ◽  
Author(s):  
M P Gordge ◽  
R W Faint ◽  
P B Rylance ◽  
G H Neild
Keyword(s):  
Renal Failure ◽  
Platelet Aggregation ◽  
Platelet Function ◽  
Bleeding Time ◽  
C Reactive Protein ◽  
Severe Renal Failure ◽  
Reactive Protein ◽  
Thromboxane Production ◽  
Von Willebrand ◽  
Willebrand Factor

SummaryBleeding time and platelet function tests were performed on 31 patients with progressive chronic renal failure (CRF) due to non-immunological (urological) causes, and compared with 22 healthy controls. Patients were classified as mild (plasma creatinine <300 μmol/l), moderate (300-600 μmol/l) or severe renal failure (>600 μmol/l). Bleeding time was rarely prolonged in mild and moderate CRF and mean bleeding time significantly elevated only in severe CRF (p <0.005). Haematocrit was the only index which correlated with bleeding time (r = -0.40). Platelet counts, collagen stimulated thromboxane generation, and platelet aggregation responses to ADP, collagen and ristocetin were all either normal or increased in all three CRF groups, but thromboxane production in clotting blood was reduced. Plasma fibrinogen, C reactive protein and von Willebrand factor (vWF) were elevated in proportion to CRF. We found no evidence that defects in platelet aggregation or platelet interaction with vWF prolong the bleeding time in patients with progressive CRF.

scholarly journals Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era

2021 ◽  
Vol 11 (02) ◽  
pp. e95-e98
Author(s):  
Sara Madureira Gomes ◽  
Rita Pissarra Teixeira ◽  
Gustavo Rocha ◽  
Paulo Soares ◽  
Hercilia Guimaraes ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Hemolytic Uremic Syndrome ◽  
Perinatal Asphyxia ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Congenital Infection ◽  
High Morbidity ◽  
Severe Renal Failure ◽  
Emergency Cesarean ◽  
Uremic Syndrome

AbstractThe atypical hemolytic uremic syndrome (aHUS) in the newborn is a rare disease, with high morbidity. Eculizumab, considered a first-line drug in older children, is not approved in neonates and in children weighing less than 5 kg. We present a 5-day-old female newborn, born at 36 weeks' twin gestation, by emergency cesarean section due to cord prolapse, with birth weight of 2,035 g and Apgar score of 7/7/7, who develops microangiopathic hemolytic anemia, thrombocytopenia, and progressive acute renal failure. In day 5, after diagnosis of aHUS, a daily infusion of fresh frozen plasma begins, with improvement of thrombocytopenia and very slight improvement in renal function. The etiologic study (congenital infection, Shiga toxin, ADAMTS13 activity, directed metabolic study) was normal. C3c was slightly decreased. On day 16 for maintenance of anemia and severe renal failure, she started 300 mg/dose eculizumab. Anemia resolves in 10 weeks and creatinine has normal values after 13 weeks of treatment. The genetic study was normal. In this case, eculizumab is effective in controlling microangiopathy and in the recovery of renal function. Diagnosis of neonatal aHUS can be challenging because of phenotypic heterogeneity and potential overlap with other manifestations that may confound it, such as perinatal asphyxia or sepsis/disseminated intravascular coagulation.

scholarly journals Temporal trends in treatment and outcomes of patients with acute coronary syndrome and concomitant moderate to severe renal failure

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Bossard ◽  
F Witassek ◽  
D Radovanovic ◽  
F Moccetti ◽  
P Erne ◽  
...  
Keyword(s):  
Renal Failure ◽  
Temporal Trends ◽  
Limited Information ◽  
Severe Renal Failure ◽  
P2y12 Inhibitors ◽  
Coronary Syndrome ◽  
Number Of Patients ◽  
Percutaneous Coronary ◽  
Coronary Syndromes ◽  
To Receive

Abstract Introduction Limited information about the management and outcomes of patients with acute coronary syndromes (ACS) and moderate to severe renal failure (RF) is available owing to underrepresentation of this population in most studies. Methods We evaluated the use of guideline-recommended therapies and in-hospital outcomes of totally 49'191 ACS patients with normal-mild renal failure (RF) (defined as eGFR &gt;45ml/min/m2) versus moderate-severe RF (eGFR &lt;45ml/min/m2) enrolled in the prospective Acute Myocardial Infarction in Switzerland (AMIS) cohort between 2002 and 2019 according to 2-year periods. Results Overall, 3'478 (7.1%) patients had moderate-severe RF. They were older (65.2+12.9 versus 77.2+10.6 years) and had significantly more comorbidities (including heart failure, cerebrovascular and peripheral vascular disease). Moderate-severe RF patients received less frequently guideline-recommended drugs, including P2Y12 inhibitors, ACEI/ARBs and statins (p&lt;0.0001). Between the first and last 2-year periods, the number of patients with moderate-severe RF and number of performed percutaneous coronary interventions (PCI) increased in this cohort (p-for-trend=0.001). At the same time, in-hospital mortality significantly decreased among ACS patients with and without RF (17.5% to 10.5% and 6.0% to 3.9%, respectively, p-for-trend=0.001 for both, see Figure). Similar trends were observed for other complications, namely cardiogenic shock and reinfarction. However, major bleedings increased significantly over time in patients with and without RF (p-for-trend=0.038 and &lt;0.001, respectively). Conclusions Outcomes of ACS patients with moderate to severe RF improved over the last two decades. Even though the rate of PCI increased in ACS patients with moderate-severe RF, they were less likely to receive guideline-recommended therapies and still suffer a high in-hospitality mortality (&gt;10%). With respect to the increasing burden of ACS patients with RF, our study implicates that more efforts should be undertaken to further improve outcomes of those patients. Funding Acknowledgement Type of funding source: None

Benign monoclonal gammopathy presenting with severe renal failure

2009 ◽  
Vol 36 (1) ◽  
pp. 115-117 ◽  
Author(s):  
Paolo Gavarotti ◽  
Felice Fortina ◽  
Daniela Costa ◽  
Giuseppe Verzetti ◽  
Valter Redoglia ◽  
...  
Keyword(s):  
Renal Failure ◽  
Monoclonal Gammopathy ◽  
Severe Renal Failure ◽  
Benign Monoclonal Gammopathy

A Study on the Distribution of Body Fluids after Rapid Saline Expansion in Normal Subjects and in Patients with Renal Insufficiency: Preferential Intravascular Deposition in Renal Failure

1983 ◽  
Vol 64 (2) ◽  
pp. 153-160 ◽  
Author(s):  
Hendrik A. Koomans ◽  
Anton B. Geers ◽  
Peter Boer ◽  
Jan C. Roos ◽  
Evert J. Dorhout Mees
Keyword(s):  
Renal Failure ◽  
Blood Volume ◽  
Plasma Volume ◽  
Extracellular Fluid ◽  
Normal Subjects ◽  
Distribution Volume ◽  
Fluid Distribution ◽  
Severe Renal Failure ◽  
Control Value ◽  
Stage Renal Disease

1. The effect of rapid intravenous infusion of 25 ml of isotonic sodium chloride solution (saline)/kg body weight on extracellular fluid volume (ECFV, 82Br distribution volume), plasma volume (131I-labelled albumin distribution volume) and blood volume (from plasma volume and packed cell volume) was studied in nine normal subjects and a group of 11 patients with end-stage renal disease (ESRD). 2. Immediately after the infusion, the increases in ECFV were equal in the two groups but the increases in plasma and blood volumes were significantly larger in the patients with ESRD. .3. Ninety minutes after the end of the infusion, the blood volume/ECFV ratio was significantly decreased from the control value in the normal subjects, but slightly increased in the patients with ESRD. 4. It is concluded that in severe renal failure the control of fluid distribution is changed in a way which leads to a preferential distribution of rapidly infused saline into the intravascular compartment.

Administration of Ticarcillin to Patients with Severe Renal Failure

Chemotherapy ◽  
1974 ◽  
Vol 20 (6) ◽  
pp. 339-341 ◽  
Author(s):  
Michael Davies ◽  
John R. Morgan ◽  
Chandar Anand
Keyword(s):  
Renal Failure ◽  
Severe Renal Failure

Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure

2017 ◽  
Vol 34 (6) ◽  
pp. 400-402 ◽  
Author(s):  
Adela Stecher ◽  
Nina Vene ◽  
Alenka Mavri ◽  
Mojca Božič Mijovski ◽  
Barbara Krevel ◽  
...  
Keyword(s):  
Renal Failure ◽  
Severe Renal Failure

scholarly journals Effects of High-Flux Hemodialysis on Inflammatory Factors and Nutritional Status in Patients with Severe Renal Failure

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Jibo Li ◽  
Xiwen Li ◽  
Gang Wang ◽  
Peiqin Jiang
Keyword(s):  
Renal Failure ◽  
Nutritional Status ◽  
Inflammatory Factors ◽  
Control Group ◽  
Observation Group ◽  
High Flux ◽  
Research Subjects ◽  
Treatment Results ◽  
Severe Renal Failure ◽  
Dialysis Treatment

Objective: To investigate the effects of high-flux hemodialysis on inflammatory factors and nutritional status in patients with severe renal failure. Methods: A total of 72 patients with severe renal failure who underwent dialysis treatment in the hospital from January 2017 to March 2019 were selected as the research subjects, and they were randomly divided into 2 groups with 36 patients each. The control group underwent low-flux hemodialysis, and the observation group underwent high-flux hemodialysis. The levels of inflammatory factors and nutritional status were compared between the two groups after treatment. Results: The levels of various inflammatory factors in the observation group were lower than those in the control group and the nutritional indexes were higher than those in the control group after 4 weeks of treatment (P<0.05). Conclusion: High-throughput hemodialysis in patients with severe renal failure can significantly reduce the levels of inflammatory factors and improve nutritional status.

Sign in / Sign up

Export Citation Format

Share Document